Vectura has agreed to a £1.55 per share takeover by US private investment company Carlyle, which values the UK drug delivery specialist at £958 million ($1.4 billion).
UK-listed Vectura has started the search for a new chief executive, after revealing current CEO James Ward-Lilley will be stepping down on 30 June after four years at the helm.
A pharma company’s core mission is to improve patient outcomes. This hinges on effectively influencing HCP clinical behaviour and driving disease education.